ASCO/EHA/ICML 2021 – Wojciech Jurczak

Wojciech Jurczak gives an overview of the advantages of new BTK inhibitors, the results of the ALPINE trial comparing zanubrutinib with ibrutinib in patients with relapsed/refractory CLL/SLL and talks about which new developments can be expected in the field of innovative BTK inhibitors in the treatment of CLL and other indications.

Here is the full ASCO/EHA/ICML 2021 report.